Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Join Prof. Jessica Lin as she explores key strategies for managing ALK+ NSCLC while prioritizing long-term patient safety

Speaker : Prof. Jessica Lin

Optimizing Treatment Options in Advanced Urothelial Carcinoma

Explore Dr. TamoJit Chaudhury’s expert insights on optimizing advanced urothelial carcinoma treatment, covering immunotherapy, targeted therapy, and clinical trial breakthroughs.

Speakers : Dr. Tamojit Chaudhury

Updates on the First Line Management of ALK+ NSCLC

In this webinar, a detailed discussion is done on Enhancing Outcomes in Advanced Lung Cancer

Speakers : Prof. Tony Mok

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Join Prof. Jessica Lin as she explores key strategies for managing ALK+ NSCLC while prioritizing long-term patient safety

Speakers : Prof. Jessica Lin

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

Join Prof. Solange Peters as she explores post-progression strategies after first-line third-generation ALK inhibitors in NSCLC.

Speakers : Prof. Solange Peters

Oropharyngeal Cancer in Relation to HPV Status

Learn about the occurrence of oropharyngeal cancer in HPV negative patients through different case presentations.

Speakers : Dr. Ashish M Kaushal

Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Dr. Rohit R Pai compares Nimotuzumab plus chemoradiotherapy vs. placebo plus chemoradiotherapy in locally advanced nasopharyngeal carcinoma (LA-NPC).

Speakers : Dr. Rohit R Pai - Speaker

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

Explore the role of Nimotuzumab in Nasopharyngeal Cancer management with Dr. Abhishek Raj, focusing on targeted therapy and improved patient outcomes.

Speakers : Dr. Abhishek Raj

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

Explore the benefits of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer with Dr. Shailesh Bondarde.

Speakers : Dr Shailesh Bondarde

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Discover how CDK4/6 inhibitors extend progression-free survival (PFS) and overall survival (OS) in HR+/HER2- metastatic breast cancer (mBC) patients.

Speakers : Dr Parveen Jain

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

Explore expert insights on first-line maintenance therapy for metastatic urothelial carcinoma in this panel discussion featuring Dr. Tushar Patil, Dr. Varun Nagori, and Dr. Amol Dongre.

Speakers : Dr Tushar Patil ,Dr Varun Nagori ,Dr Amol Dongre


Recommended News For You

Most women with early-stage breast cancer can anticipate living long lives, according to experts.

In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

Hematocrit Stabilized in Polycythemia Vera Under Novel Hepcidin Mimetic Treatment.

Knowing about and avoiding bladder cancer.

According to JAMA, even four minutes a day of exercise can lower the risk of cancer.

Opposition to the Surgical Lymph Node Sampling Rule for Lung Resection.

The response of bipolar patients to lithium may be predicted by ancestry.

Recommended Articles For You

Tertiary Lymphoid Structures: Pivotal Players in Cancer Prognosis and Therapeutic Response 

Uncovering the Hidden Picture: Using Ultrasound to Diagnose Breast Cancer 

Beyond Immunotherapy: Emerging Novel Treatments for Small Cell Lung Cancer 

Oncologic Emergencies: Diagnosis and Treatment 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Effect of Common Steroids on Cancer Treatments.

2.

Eltrombopag Improves Outcomes in Kids With Newly Diagnosed ITP

3.

Improved end-of-life conversations for cancer patients are identified by a new study.

4.

Exercise may help breast cancer survivors manage weight

5.

The self-sacrificing nature of breast cancer cells has been identified as a possible reason for relapse.

1.

Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment

2.

Subchorionic Hematoma: Causes, Symptoms, and Treatment 

3.

How AI is Transforming Diagnostics, Drug Discovery, and Personalized Oncology

4.

Next-Gen Cancer Therapies: Radiopharmaceuticals, Immuno-Oncology, and Biologic Breakthroughs

5.

Case Study: The Role of JAK Inhibitors in Myeloproliferative Disorders

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men

2.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

3.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

5.

Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot